What is Freespira?
Freespira offers an FDA-cleared, non-invasive, drug-free, four-week at-home treatment for panic attacks and panic symptoms. Authorized and supervised by licensed healthcare providers, Freespira is clinically validated to reduce or eliminate panic attacks and other symptoms of panic disorder. The treatment addresses chronic hyperventilation, a common issue among individuals with panic disorder, by stabilizing respiration rate and exhaled carbon dioxide levels, thereby mitigating anxiety-driven avoidance behaviors.
How much funding has Freespira raised?
Freespira has raised a total of $10M across 1 funding round:
Unspecified
$10M
Unspecified (2020): $10M with participation from Aphelion Capital LLC, Lightspeed Venture Partners, and Medvest Capital
Key Investors in Freespira
Aphelion Capital LLC
Aphelion Capital LLC is an investor in this funding round. Further details on their investment focus are not publicly available.
Lightspeed Venture Partners
Lightspeed Venture Partners (lsvp.com) is a global multistage venture capital firm that invests in early and growth-stage technology companies across various sectors, including enterprise software, consumer, fintech, and infrastructure.
Medvest Capital
Medvest Capital is a venture capital firm established in 2013 that specializes in investing in early-stage medical device companies, aiming to improve patient outcomes and accelerate product development.
What's next for Freespira?
The substantial enterprise-level funding Freespira has received indicates a strong market validation and provides the capital necessary for scaling its innovative treatment. This strategic investment is likely to fuel further clinical research, expand market reach to more healthcare providers and patients, and enhance the platform's capabilities. The company is well-positioned to become a leader in non-pharmacological treatments for panic disorder.
See full Freespira company page
